Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Cash flows from operating activities:
Net loss	$ (50,795,000)	$ (40,790,000)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	496,000	360,000
Net (accretion) and amortization of investments in marketable securities	(528,000)	(1,807,000)
Change in fair value of preferred stock tranche right liability		7,390,000
Non-cash lease expense	894,000	315,000
Stock-based compensation expense	8,429,000	3,845,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(5,144,000)	(1,170,000)
Other assets	(548,000)	51,000
Accounts payable	1,216,000	(1,040,000)
Accrued expenses and other current liabilities	784,000	(795,000)
Operating lease liabilities	(111,000)	(326,000)
Net cash used in operating activities	(45,307,000)	(33,967,000)
Cash flows from investing activities
Purchases of short-term investments	(56,093,000)	(183,231,000)
Maturities of short-term investments	100,033,000	36,240,000
Purchases of property and equipment	(313,000)	(2,039,000)
Net cash provided by (used in) investing activities	43,627,000	(149,030,000)
Cash flows from financing activities
Proceeds from initial public offering and concurrent private placement, net of underwriter discounts and commissions and deferred offering costs		159,099,000
Proceeds from issuance of Series B convertible preferred stock, net of issuance costs paid		63,913,000
Proceeds from exercise of stock options	6,000
Repurchase of unvested restricted common stock	(1,000)
Payment of deferred offering costs	(63,000)
Net cash (used in) provided by financing activities	(58,000)	223,012,000
Net (decrease) increase in cash, cash equivalents, and restricted cash	(1,738,000)	40,015,000
Cash, cash equivalents, and restricted cash at beginning of period	56,910,000	70,254,000
Cash, cash equivalents, and restricted cash at end of period	55,172,000	110,269,000
Supplemental disclosure for noncash investing and financing activities:
Settlement of Series B preferred stock tranche right liability		11,590,000
Right-of-use assets obtained in exchange for operating lease liabilities	10,499,000
Deferred offering costs included in accounts payable and accrued expenses at period end	262,000	1,394,000
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	55,067,000	110,164,000
Restricted cash	105,000	105,000
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 55,172,000	110,269,000
Series A Convertible Preferred Stock
Supplemental disclosure for noncash investing and financing activities:
Conversion of convertible preferred stock into common stock upon closing of initial public offering		89,487,000
Series B Convertible Preferred Stock
Supplemental disclosure for noncash investing and financing activities:
Conversion of convertible preferred stock into common stock upon closing of initial public offering		$ 145,252,000